Skip to main content
Jose Villasboas Bisneto, MD, Oncology, Rochester, MN, Mayo Clinic Hospital - Rochester

JoseCaetanoVillasboas BisnetoMD

Oncology Rochester, MN

Senior Associate Consultant / Assistant Professor of Medicine and Oncology

Dr. Villasboas Bisneto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Villasboas Bisneto's full profile

Already have an account?

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2013 - 2017
  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Internal Medicine, 2009 - 2013
  • Federal University of Bahia Faculty of Medicine
    Federal University of Bahia Faculty of MedicineClass of 2008, MD

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2013 - 2024
  • FL State Medical License
    FL State Medical License 2012 - 2014

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Tumor ADAM10/ADAM17-Mediated PD-L1 Loss May Predict Poor Outcomes in Diffuse Large B Cell Lymphoma
    Jose Villasboas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Mass Cytometry Identifies a Novel Signature for Myeloid-Derived Suppressor-Cells in WaldenstromÍs Macroglobulinemia
    Jose Villasboas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
    Jose Villasboas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relap... 
    2019 ASCO Annual Meeting - 6/1/2019

Other Languages

  • Portuguese, Spanish

Hospital Affiliations